UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 232

Sortiert nach

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Journal of clinical oncology, 2016-09, Vol.34 (26), p.3119-3125

2016

Volltextzugriff (PDF)

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Clinical cancer research, 2016-11, Vol.22 (22), p.5461-5471

2016

Volltextzugriff (PDF)

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Clinical cancer research, 2023-02, Vol.29 (4), p.754-763

2023

Volltextzugriff (PDF)

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity

Clinical cancer research, 2005-07, Vol.11 (13), p.4912-4922

2005

Volltextzugriff (PDF)

Myc-mediated transcriptional repression by recruitment of histone deacetylase

Cancer research (Chicago, Ill.), 2008-05, Vol.68 (10), p.3624-3629

2008

Volltextzugriff (PDF)

Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.874-882

2023

Volltextzugriff (PDF)

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Future oncology (London, England), 2023-12, Vol.19 (38), p.2505-2516

2023

Volltextzugriff (PDF)

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Future oncology (London, England), 2023-11, Vol.19 (34), p.2277-2289

2023

Volltextzugriff (PDF)

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

European journal of cancer (1990), 2013-05, Vol.49 (8), p.1815-1824

2013

Volltextzugriff (PDF)

The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis

The Journal of biological chemistry, 2003-08, Vol.278 (34), p.32465-32470

2003

Volltextzugriff (PDF)

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically-Based Pharmacokinetic Simulations

Journal of clinical pharmacology, 2013-02, Vol.53 (2), p.217-227

2013

Volltextzugriff (PDF)

Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase

The Journal of biological chemistry, 2003-06, Vol.278 (23), p.20593-20602

2003

Volltextzugriff (PDF)

Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells

International journal of cancer, 2001-12, Vol.96 (6), p.327-333

2001

Volltextzugriff (PDF)

Crashing waves of destruction: the cell cycle and APC(Cdh1) regulation of SCF(Skp2)

Cancer cell, 2004-04, Vol.5 (4), p.305-306

2004

Volltextzugriff (PDF)

Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-996-S-996

2024

Volltextzugriff (PDF)

Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells

Molecular cancer therapeutics, 2004-08, Vol.3 (8), p.985-992

2004

Volltextzugriff (PDF)

T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4087-4087

2021

Volltextzugriff (PDF)

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.4502-4502

2016

Volltextzugriff (PDF)

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9029-9029

2016

Volltextzugriff (PDF)

NF- Kappa B1 (p50) Homodimers Contribute to Transcription of the bcl-2 Oncogene

The Journal of biological chemistry, 2001-11, Vol.276 (48), p.45380-45386

2001

Volltextzugriff (PDF)

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3017-3017

2014

Volltextzugriff (PDF)

Abstract 1281: Exploratory analysis of microRNAs as predictive markers of benefit from cetuximab in metastatic colorectal cancer

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.1281-1281

2011

Volltextzugriff (PDF)

A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS3108-TPS3108

2013

Volltextzugriff (PDF)

CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS8603-TPS8603

2012

Volltextzugriff (PDF)

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5010-5010

2014

Volltextzugriff (PDF)

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(210)
Mit Volltextzugriff
(190)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(232)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity

Myc-mediated transcriptional repression by recruitment of histone deacetylase

Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis

Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically-Based Pharmacokinetic Simulations

Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase

Protease inhibitors restore radiation‐induced apoptosis to Bcl‐2‐expressing lymphoma cells

Crashing waves of destruction: the cell cycle and APC(Cdh1) regulation of SCF(Skp2)

Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5-FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY

Inhibition of constitutively activated nuclear factor-κB radiosensitizes human melanoma cells

T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer

NF- Kappa B1 (p50) Homodimers Contribute to Transcription of the bcl-2 Oncogene

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract 1281: Exploratory analysis of microRNAs as predictive markers of benefit from cetuximab in metastatic colorectal cancer

A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies

CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)

Suchergebnisse filtern